General Pathology — MCQs

General Pathology Indian Medical PG Practice Questions and MCQs

Question 261: Which of the following is NOT observed during the inflammatory stage of wound healing?

A. Angiogenesis (Correct Answer)
B. Chemotaxis
C. Increased capillary permeability
D. Cytokine and chemotactic factor release

Explanation: Wound healing is a complex process divided into three overlapping phases: **Inflammation, Proliferation, and Remodeling.** **Why Angiogenesis is the Correct Answer:** Angiogenesis (the formation of new blood vessels) is a hallmark of the **Proliferative Phase**, not the inflammatory phase [1]. It typically begins 3–5 days after injury, driven by growth factors like VEGF and FGF. During this stage, angiogenesis combines with fibroblast proliferation to form **granulation tissue**, which serves as the foundation for tissue repair [1]. **Analysis of Incorrect Options:** * **Increased Capillary Permeability:** This occurs in the earliest minutes of the **Inflammatory Phase**. Histamine and leukotrienes cause endothelial gaps, leading to the hallmark swelling (edema) and allowing plasma proteins to reach the site of injury. * **Cytokine and Chemotactic Factor Release:** Upon injury, mast cells and resident macrophages release mediators (TNF-α, IL-1) to initiate the inflammatory cascade. * **Chemotaxis:** This is the process by which inflammatory cells (neutrophils followed by macrophages) migrate toward the injury site along a chemical gradient [2]. It is the defining cellular event of the inflammatory phase. **NEET-PG High-Yield Pearls:** * **Order of Cell Arrival:** Neutrophils (first 24–48 hours) → Macrophages (48–72 hours). Macrophages are the "master cells" of wound healing [1]. * **Granulation Tissue vs. Granuloma:** Do not confuse them. Granulation tissue is a sign of healing (vessels + fibroblasts); a granuloma is a sign of chronic inflammation. * **Type of Collagen:** In the proliferative phase, **Type III Collagen** is deposited; in the remodeling phase, it is replaced by **Type I Collagen** (stronger). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 115, 117-119. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 188-189.

Question 262: A 40-year-old pregnant female in her third trimester presents with bilateral leg swelling. Which of the following statements about the type of thrombosis most likely to be present in this patient is true?

A. Pale platelet layer alternating with a dark red cell layer is present.
B. Incomplete lumen occlusion is present.
C. Thrombosis grows in an antegrade manner. (Correct Answer)
D. It causes ischemia and infarction of organs.

Explanation: The clinical scenario describes a pregnant female in her third trimester with bilateral leg swelling, which is a classic presentation for **Deep Vein Thrombosis (DVT)** [1]. Pregnancy is a hypercoagulable state (Virchow’s Triad) due to increased clotting factors and venous stasis from the gravid uterus compressing the inferior vena cava [2]. **1. Why the Correct Answer is Right:** * **Option C (Antegrade growth):** Venous thrombi (Phlebothrombosis) characteristically propagate or grow in the **direction of blood flow (antegrade)**, which means they extend toward the heart. In contrast, arterial thrombi grow in a retrograde manner (against the flow). **2. Why the Incorrect Options are Wrong:** * **Option A:** This describes **Lines of Zahn**. While these can be seen in venous thrombi, they are much more prominent and characteristic of **arterial thrombi** or thrombi formed in areas of high flow (heart). Venous thrombi are typically "red/stasis thrombi" with less distinct laminations. * **Option B:** Venous thrombi in the lower extremities are almost always **occlusive** [1], forming a long cast of the vessel lumen, whereas arterial thrombi are often mural (incomplete occlusion) unless in small arteries. * **Option D:** Venous thrombi primarily cause **congestion and edema** due to impaired drainage [1]. Ischemia and infarction are the hallmarks of **arterial thrombosis**, which blocks the oxygenated blood supply to tissues [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Virchow’s Triad:** Endothelial injury, Stasis, and Hypercoagulability [3]. * **Most common site for DVT:** Deep leg veins (e.g., popliteal, femoral, and iliac veins) [1]. * **Major Complication:** The most feared consequence of DVT is **Pulmonary Embolism (PE)**. * **Morphology:** Venous thrombi are often called "red thrombi" because they contain more enmeshed red blood cells compared to the "pale thrombi" of arteries. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 143-144. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 141-142. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 142-143.

Question 263: An increase in the size of a cell in response to stress is called hypertrophy. Which of the following does not represent an example of smooth muscle hypertrophy as an adaptive response to a relevant situation?

A. Urinary bladder in urine outflow obstruction
B. Gallbladder in chronic cholecystitis
C. Triceps in body-builders (Correct Answer)
D. Uterus enlargement during pregnancy

Explanation: ### Explanation **1. Why "Triceps in body-builders" is the correct answer:** Hypertrophy is an increase in the size of cells resulting in an increase in the size of the organ [1]. While the triceps do undergo hypertrophy in bodybuilders, the triceps are composed of **skeletal muscle**, not **smooth muscle**. The question specifically asks for an example that does *not* represent smooth muscle hypertrophy. Skeletal muscle cells are permanent cells (non-dividing) and adapt to increased workload solely through hypertrophy. **2. Analysis of Incorrect Options (Examples of Smooth Muscle Hypertrophy):** * **Urinary bladder in urine outflow obstruction:** In conditions like Benign Prostatic Hyperplasia (BPH), the bladder smooth muscle (detrusor) undergoes hypertrophy to generate higher pressure to overcome the resistance [2]. * **Gallbladder in chronic cholecystitis:** Persistent irritation or obstruction (e.g., by stones) leads to thickening of the gallbladder wall due to smooth muscle hypertrophy. * **Uterus enlargement during pregnancy:** This is a classic physiological example involving **both** hypertrophy and hyperplasia of the uterine smooth muscle (myometrium), stimulated by estrogen [1], [2]. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Mechanism:** Hypertrophy is driven by increased synthesis of structural proteins and organelles, often mediated by PI3K/AKT pathways or G-protein coupled receptors [1]. * **Cell Type Matters:** * **Skeletal/Cardiac Muscle:** Undergo *hypertrophy only* (permanent cells). * **Smooth Muscle:** Can undergo *both* hypertrophy and hyperplasia (labile/stable cells) [2]. * **Pathological vs. Physiological:** Cardiac hypertrophy due to hypertension is pathological; uterine growth in pregnancy is physiological [1]. * **Limit of Hypertrophy:** If the stress is not relieved, hypertrophied muscle (especially cardiac) can reach a limit beyond which degenerative changes (fragmentation of myofibrils) lead to organ failure [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 45-46. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 85-87.

Question 264: Autolysis is due to the activity of which cellular component?

A. Lecithinase
B. Lipase
C. Lysosomes (Correct Answer)
D. ATPase

Explanation: **Explanation:** **Autolysis** refers to the process of self-digestion of a cell after death. It occurs due to the release of hydrolytic enzymes from the cell's own **lysosomes**. [1] 1. **Why Lysosomes are correct:** Lysosomes are often called the "suicide bags" of the cell. [1] They contain a variety of acid hydrolases (proteases, nucleases, glycosidases). In a living cell, these enzymes are sequestered within the lysosomal membrane. Upon cell death or severe injury, the membrane integrity is lost, and these enzymes leak into the cytoplasm, digesting the cell's own proteins and organelles. [1] This is a hallmark of post-mortem changes and certain types of necrosis (like liquefactive necrosis). 2. **Why other options are incorrect:** * **Lecithinase:** This is an exotoxin (Alpha-toxin) produced by *Clostridium perfringens*. While it causes cell membrane destruction (Gas Gangrene), it is an external bacterial enzyme, not the primary driver of internal cellular autolysis. * **Lipase:** While lipases are involved in enzymatic fat necrosis (commonly seen in acute pancreatitis), they are specific to lipid breakdown rather than the generalized self-digestion of all cellular components. [2] * **ATPase:** This is an enzyme that hydrolyzes ATP to yield energy. [3] While ATP depletion is a key event in cell injury, the enzyme itself does not digest the cell structure. [1] **Clinical Pearls for NEET-PG:** * **Autolysis vs. Heterolysis:** Autolysis is digestion by the cell's *own* enzymes; Heterolysis is digestion by enzymes from *extrinsic* sources (e.g., infiltrating neutrophils). * **Morphology:** Autolysis is characterized by cytoplasmic eosinophilia and nuclear changes (pyknosis, karyorrhexis, and karyolysis). * **High-Yield Fact:** Autolysis is a purely chemical process and does **not** involve an inflammatory response, distinguishing it from necrosis in a living organism. [4] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 60-61. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 55. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 51-53. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 71.

Question 265: What is the characteristic marker for squamous cell carcinoma?

A. Vimentin
B. Cytokeratin (Correct Answer)
C. Desmin
D. Myogenin

Explanation: **Explanation:** The correct answer is **Cytokeratin (B)**. **Why Cytokeratin is correct:** Cytokeratins are intermediate filaments found specifically in the intracytoplasmic cytoskeleton of **epithelial tissue**. Since Squamous Cell Carcinoma (SCC) is a malignant tumor arising from the epithelium, it consistently expresses cytokeratin. In pathology, Immunohistochemistry (IHC) markers for cytokeratin (such as CK5/6 or p40) are used to confirm the diagnosis of SCC and differentiate it from other poorly differentiated tumors [2]. **Why other options are incorrect:** * **Vimentin (A):** This is the characteristic intermediate filament for **mesenchymal cells**. It is a marker for sarcomas (e.g., osteosarcoma, liposarcoma) and is also expressed in normal fibroblasts, endothelium, and leukocytes. * **Desmin (C):** This is a marker for **muscle cells** (both skeletal and smooth muscle). It is used to identify tumors like leiomyomas or rhabdomyosarcomas. * **Myogenin (D):** This is a transcription factor specific to **skeletal muscle differentiation**. It is a highly specific marker for Rhabdomyosarcoma. **High-Yield Clinical Pearls for NEET-PG:** * **Pancytokeratin (AE1/AE3):** A "cocktail" of antibodies used as a primary screening marker for any carcinoma [1]. * **p40 and CK5/6:** These are the most specific IHC markers for Squamous Cell Carcinoma [2]. * **GFAP:** Marker for glial cells (Astrocytomas). * **Synaptophysin/Chromogranin:** Markers for Neuroendocrine tumors. * **S-100:** Marker for Melanoma, Schwannoma, and Langerhans Cell Histiocytosis. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 208-209. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 644-645.

Question 266: What is the definition of septicemia?

A. Bacteria in the blood
B. Toxins in the blood
C. Pus in the blood
D. Multiplication of bacteria and toxins in the blood (Correct Answer)

Explanation: ### Explanation **Septicemia** is a systemic clinical syndrome characterized by the active **multiplication of pathogenic microorganisms and the presence of their toxins** in the bloodstream [1]. Unlike transient states, septicemia implies that the body’s immune system is overwhelmed, leading to systemic inflammatory response syndrome (SIRS) and potential multi-organ dysfunction [2]. #### Analysis of Options: * **Option D (Correct):** Septicemia is defined by both the proliferation of bacteria and the accumulation of their metabolic products (toxins) in the blood, leading to clinical symptoms like high-grade fever, chills, and hypotension. * **Option A (Bacteremia):** This refers simply to the presence of bacteria in the blood (e.g., after vigorous tooth brushing). It is often transient and does not necessarily involve multiplication or clinical illness. * **Option B (Toxemia):** This is the presence of toxins in the blood (e.g., Tetanus or Diphtheria) without the active multiplication of the bacteria themselves within the bloodstream. * **Option C (Pyemia):** This is a specific type of septicemia where pyogenic (pus-forming) organisms circulate in the blood, leading to the formation of multiple secondary abscesses in distant organs. #### NEET-PG High-Yield Pearls: 1. **Sepsis vs. Septicemia:** In modern clinical practice (Sepsis-3 criteria), "Sepsis" is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [2]. "Septicemia" is an older, more descriptive laboratory/pathological term. 2. **Septic Shock:** Defined as sepsis with persistent hypotension requiring vasopressors to maintain MAP ≥65 mmHg and having a serum lactate level >2 mmol/L despite adequate fluid resuscitation [2]. 3. **Common Triggers:** Gram-negative bacteria (due to Endotoxin/LPS) are the most frequent causes of septic shock [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 64-65. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 110-111.

Question 267: All of the following are features of stem cells except?

A. Found in yolk sac
B. Found in peripheral circulation
C. Used in gene therapy (Correct Answer)
D. Some stem cells are unipotent

Explanation: **Explanation:** Stem cells are undifferentiated cells characterized by two hallmark properties: **Self-renewal** (ability to maintain their population) and **Asymmetric division** (ability to differentiate into specific lineages) [1]. **Why Option C is the Correct Answer (The "Except"):** While stem cells are a major focus of regenerative medicine, they are **not** a defining "feature" or inherent property of stem cells themselves. Gene therapy involves the delivery of nucleic acids into a patient's cells as a drug to treat disease. While stem cells can be *targets* or *vehicles* for gene therapy (e.g., modifying hematopoietic stem cells in SCID), gene therapy is a therapeutic application, not a biological characteristic of the cell. **Analysis of Other Options:** * **Option A (Found in yolk sac):** During embryogenesis, the yolk sac is the first site of hematopoiesis. Hematopoietic stem cells (HSCs) originate in the extraembryonic mesoderm of the yolk sac before migrating to the Liver and eventually the Bone Marrow. * **Option B (Found in peripheral circulation):** Although primarily resident in the bone marrow, a small number of stem cells (HSCs) circulate in the peripheral blood [3]. This can be increased using "mobilizing agents" like G-CSF for peripheral blood stem cell transplantation. * **Option D (Some stem cells are unipotent):** Stem cells exist in a hierarchy of potency [2]. While embryonic stem cells are pluripotent, adult stem cells can be multipotent or **unipotent** (e.g., Basal cells of the epidermis or Spermatogonial stem cells), which can only produce one specific cell type but retain the property of self-renewal [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Potency Hierarchy:** Totipotent (Zygote) → Pluripotent (Embryonic Stem Cells) → Multipotent (HSC) → Unipotent (Skin basal cells). * **Best Marker for HSCs:** CD34+ (used for flow cytometry and harvesting). * **Induced Pluripotent Stem Cells (iPS):** Created by reprogramming adult somatic cells using transcription factors (Oct3/4, Sox2, c-Myc, and Klf4). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. With Illustrations By, pp. 38-40. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 84-85. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 104-105.

Question 268: Oncocytes are a modified form of which organelle?

A. Nucleolus
B. Endoplasmic Reticulum
C. Mitochondria (Correct Answer)
D. Lysosomes

Explanation: **Explanation:** **Oncocytes** are specialized epithelial cells characterized by an abundant, granular, and intensely eosinophilic (pink) cytoplasm. This distinct appearance is due to the **massive accumulation of mitochondria**, which can occupy up to 60% of the cell volume [1]. 1. **Why Mitochondria is correct:** The granular texture seen under light microscopy corresponds to thousands of mitochondria [1]. These organelles are often structurally abnormal (e.g., enlarged or with stacked cristae) and dysfunctional. The eosinophilia occurs because the mitochondrial inner membrane proteins bind strongly to the acidic dye, eosin. 2. **Why other options are incorrect:** * **Nucleolus:** While oncocytes may have prominent nucleoli, the defining feature of "oncocytic change" is cytoplasmic, not nuclear. * **Endoplasmic Reticulum:** Excessive ER (specifically Rough ER) typically results in cytoplasmic **basophilia** (blue tint), as seen in plasma cells, not the eosinophilia seen in oncocytes. * **Lysosomes:** An accumulation of lysosomes is characteristic of **Granular Cell Tumors** (e.g., Abrikossoff tumor), which can mimic oncocytes but are distinct entities. **High-Yield Clinical Pearls for NEET-PG:** * **Warthin’s Tumor (Adenolymphoma):** The most common salivary gland tumor showing prominent oncocytic cells arranged in double layers. * **Oncocytoma:** A benign renal tumor characterized by a "mahogany brown" appearance and a **central stellate scar** [2]. * **Hürthle Cells:** These are oncocytic variants of follicular cells found in the thyroid, commonly seen in **Hashimoto’s Thyroiditis** and Hürthle cell neoplasms. * **Phosphotungstic Acid Hematoxylin (PTAH):** This stain can be used to demonstrate the mitochondrial granules in oncocytes. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1103-1104. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Kidney, p. 959.

Question 269: Birbeck granules in the cytoplasm are seen in which of the following cell types?

A. Langerhans cells (Correct Answer)
B. Mast cells
C. Myelocytes
D. Thrombocytes

Explanation: **Explanation:** **Birbeck granules** are the pathognomonic ultrastructural hallmark of **Langerhans cells** [1][2]. These are specialized dendritic cells (antigen-presenting cells) primarily located in the stratum spinosum of the epidermis [2]. 1. **Why Langerhans cells are correct:** Under electron microscopy, Birbeck granules appear as rod-shaped, pentalaminar cytoplasmic organelles with a central striated line [1]. They often feature a bulbous expansion at one end, giving them a characteristic **"tennis racket" appearance** [1]. These granules contain the protein **Langerin (CD207)** and are involved in the endocytosis and processing of antigens [1]. 2. **Why other options are incorrect:** * **Mast cells:** Characterized by membrane-bound granules containing histamine, heparin, and ECF-A. They show a "scroll-like" or "fingerprint" pattern on electron microscopy, not Birbeck granules. * **Myelocytes:** These are precursors in granulopoiesis. They contain primary (azurophilic) and secondary (specific) granules, but lack the specialized Birbeck structure. * **Thrombocytes (Platelets):** Contain alpha-granules (fibrinogen, vWF) and dense granules (ADP, Calcium, Serotonin), but do not possess Birbeck granules. **High-Yield Clinical Pearls for NEET-PG:** * **Langerhans Cell Histiocytosis (LCH):** A group of disorders (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease) characterized by the proliferation of these cells [1]. * **Immunohistochemistry (IHC) Markers:** Langerhans cells are positive for **S-100**, **CD1a**, and **CD207 (Langerin)** [1]. * **Origin:** Unlike other skin cells, Langerhans cells originate from the **bone marrow** (monocyte-macrophage lineage). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 629-630. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 200.

Question 270: Which type of cell mediates the immunological reaction against a transplanted organ?

A. B-cells
B. NK cells
C. T-cells (Correct Answer)
D. Granulocytes

Explanation: **Explanation:** The immunological reaction against a transplanted organ (graft rejection) is primarily a **cell-mediated immune response** driven by **T-cells** [1], [3]. **Why T-cells are the correct answer:** T-cells recognize the donor’s **MHC (HLA) molecules** as foreign. This occurs via two pathways [1]: 1. **Direct Pathway:** Host T-cells recognize MHC molecules on the surface of donor APCs (present within the graft) [1]. 2. **Indirect Pathway:** Host APCs present processed donor MHC peptides to host T-cells [5]. **CD8+ T-cells** cause direct cytotoxicity to graft cells, while **CD4+ T-cells** release cytokines (like IFN-γ) that trigger delayed-type hypersensitivity (DTH) and macrophage activation, leading to tissue injury [1], [3]. **Analysis of Incorrect Options:** * **A. B-cells:** While B-cells produce antibodies that contribute to *Hyperacute* rejection (pre-formed antibodies) and *Chronic* rejection, they are not the primary mediators of the classic cellular rejection response [3]. * **B. NK cells:** These are part of the innate immune system. While they play a minor role in "missing self" recognition, they are not the principal drivers of transplant immunity [4]. * **D. Granulocytes:** Neutrophils and eosinophils are secondary effectors of inflammation and are not responsible for the specific immunological recognition of the graft. **High-Yield Clinical Pearls for NEET-PG:** * **Hyperacute Rejection:** Occurs within minutes; mediated by **Pre-formed Antibodies** (Type II Hypersensitivity). * **Acute Rejection:** Occurs within days to weeks; primarily **T-cell mediated** (Type IV Hypersensitivity) [2]. * **Chronic Rejection:** Occurs months to years; characterized by **intimal fibrosis** and "vanishing bile duct syndrome" (liver) or "bronchiolitis obliterans" (lung). * **GVHD (Graft vs Host Disease):** Occurs when immunocompetent T-cells in the *graft* attack an immunodeficient *host*. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 240. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 173-174. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 180-181. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 207-208. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 240-241.

Practice by Chapter

Cell Injury and Cell Death

Practice Questions

Adaptations of Cellular Growth

Practice Questions

Accumulations and Deposits

Practice Questions

Acute and Chronic Inflammation

Practice Questions

Tissue Repair and Wound Healing

Practice Questions

Hemodynamic Disorders

Practice Questions

Genetic Disorders

Practice Questions

Environmental Pathology

Practice Questions

Nutritional Diseases

Practice Questions

Molecular Basis of Disease

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free